ImmuPharma (LSE:IMM) reported a reduced loss of £1.8 million for 2025, while maintaining broadly stable operating costs and ending the year with a cash balance of £1.4 million. The company subsequently strengthened its financial position through a £6.47 million equity fundraising completed in April 2026, providing additional support for the advancement of its development pipeline.
During the year, ImmuPharma continued progressing its P140 autoimmune platform through the generation of new mechanistic data, alongside the filing of a patent covering both a companion diagnostic and precision treatment approach targeting Type M immune disorders. The company is also preparing the platform for late-stage clinical development and potential licensing discussions. Management said these developments could position P140 as a potential future standard of care across several autoimmune disease indications, while ongoing talks with prospective partners are aimed at securing a value-enhancing licensing agreement during 2026.
ImmuPharma additionally advanced Kapiglucagon as a strategic metabolic disease asset by beginning IND-enabling studies and evaluating a potential 505(b)(2) regulatory pathway. The company also strengthened its leadership structure through internal scientific promotions and the appointment of a new independent non-executive director.
The company’s outlook continues to be weighed down by weak financial fundamentals, including minimal revenue generation, ongoing losses, persistent cash burn and negative shareholder equity. Technical indicators are mixed but moderately supportive relative to the long-term 200-day moving average, while valuation remains constrained by the absence of earnings and dividend yield support.
More about ImmuPharma
ImmuPharma PLC (LSE:IMM) is a UK-listed biotechnology company focused on the discovery and development of peptide-based therapeutics targeting autoimmune and metabolic diseases. Its lead programme is the P140 autoimmune technology platform, while additional pipeline assets include Kapiglucagon for metabolic disease and Type 1 diabetes applications. The company’s strategy centres on precision medicine approaches and partnering opportunities with larger global pharmaceutical groups.
Leave a Reply